© 2017 Pharmstandard Ventures
Aquinox investment
03.04.2013
Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has secured U.S. $18 million in the close of a Series C financing led by Johnson & Johnson Development Corporation. New investor Inbio Ventures participated in the financing along with existing investors: Pfizer Venture Investments, Ventures West Capital, and Baker Brothers Investments.
Fullpress-release
Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has secured U.S. $18 million in the close of a Series C financing led by Johnson & Johnson Development Corporation. New investor Inbio Ventures participated in the financing along with existing investors: Pfizer Venture Investments, Ventures West Capital, and Baker Brothers Investments.
Fullpress-release